Collaborative Arrangements - CRISPR Therapeutics AG (Details) - CRISPR Therapeutics	Oct. 26, 2015 USD ($) target
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Right to license, number of targets (up to) | target	6
Up-front payment	$ 75,000,000
Investment in collaborative partner, pursuant to convertible loan agreement	30,000,000
Collaborative funding	75,000,000
Collaborative arrangement development and regulatory potential milestone payments maximum	$ 420,000,000
Prior to marketing approval, time period of notice required to terminate (in days)	90 days
Subsequent to marketing approval, time period of notice required to terminate (in days)	270 days